Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Preparedness of China’s health care system to provide access to a disease-modifying Alzheimer’s treatment
Expanding the use of brief cognitive assessments to detect suspected early-stage cognitive impairment in primary care
A framework for addressing Alzheimer’s disease: Without a frame, the work has no aim
Improving community health-care systems’ early detection of cognitive decline and dementia
Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force
Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment
Preparedness of the Brazilian health-care system to provide access to a disease-modifying Alzheimer’s disease treatment
Designing the next-generation clinical carepathway for Alzheimer’s disease
